Stockreport

Cybin Provides Corporate Update on Upcoming Clinical Milestones [Yahoo! Finance]

Cybin Inc. Common Shares  (CYBN) 
PDF - 12-month efficacy data from Phase 2 study of CYB003 in MDD expected in early Q4 2024 - - Phase 2 topline efficacy and safety results for CYB004 in Generalized Anxie [Read more]